Pharmacy News

The treatment reduces the risk of disease progression or death in such patients by 70% vs placebo.

Stelara, Keytruda and Tecentriq were also among the extensions of therapeutic indication.

The funding will support 10,000 young people from all backgrounds to get a career in the NHS.

The company has readjusted its prediction for its earnings per share to decline in the range of -3% to -5% at CER, as opposed to the previous -5% to -9%.

The guideline aims to support health professionals in making accurate diagnoses and providing effective treatments.

The CMA alleges that Alliance Healthcare bought equal volumes of nitrofurantoin from the companies to discourage competing.

The trial met its primary efficacy endpoint of a mean change in haemoglobin from baseline averaged over weeks 23-27.

The antivirus programs include investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.

The review will cover NICE’s technology appraisals, highly specialised technologies, medical technologies, and diagnostics assessment programmes.

The company is also exploring several potential options for PrEP, including a drug-eluting implant and a once-monthly oral formulation.

The treatment has been approved in adult patients with non-Hodgkin’s lymphoma.

The clinic will offer access to medicinal cannabis for all conditions acknowledged to benefit from it.

New Home Office statistics show a decrease of 7% on last year, and the lowest number of procedures since 2007.

The service will offer local pharmacy appointments to anyone calling NHS 111 about the minor conditions, such as earache or a sore throat.

The treatment combines clinical psychology, neuroscience and innovative technology including machine learning.

The Fight for Sight funded project uses AI to extract ‘hidden’ information from retinal images of patients with the rare eye condition.

Testing men for faults in DNA repair genes in their tumours could identify those most likely to respond to the new type of treatment.

The Oberoi SPAF & Case Finding Service ensures high-risk AF patients receive oral anti-coagulants, helping prevent strokes.

The PharmaTimes Medical & Scientific Excellence Awards have been praised by last year’s finalists on it’s great learning and development process.

The agreement provides Mallinckrodt with an exclusive worldwide license for C3 (SLN500) - a preclinical asset that targets a specific protein in the complement pathway.